NCT00116701已完成3 期
A Study to Evaluate the Efficacy of Converting From Intravenous or Subcutaneous rHuEPO to Intravenous Darbepoetin Alfa (Aranesp®) in Subjects With Chronic Kidney Disease Receiving Haemodialysis
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Amgen
- 入组人数
- 200
- 主要终点
- Treatment period 1: Mean haemoglobin during the evaluation period (weeks 21-24)
研究概览
简要总结
Treatment period 1:To demonstrate that switching HD subjects with a baseline haemoglobin (Hb) ≥ 10 g/dL and ≤ 13 g/dL from either subcutaneous (SC) or intravenous (IV) rHuEPO to IV darbepoetin alfa results in a mean Hb > 11 g/dL.
Treatment Period 2:To demonstrate that switching subjects with a Hb > 11 g/dL and ≤ 13 g/dL from once weekly IV darbepoetin alfa to once every 2 weeks (Q2W) maintains the mean Hb at > 11 g/dL.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •at least 18 years old - Diagnosis of chronic kidney disease (CKD) and receiving dialysis for at least 3 months prior to screening - Baseline Hb level greater than or equal to 10.0 g/dL and less than or equal to 13.0 g/dL - Adequate iron stores (defined as serum ferritin greater than or equal to 100 µg/L or transferrin saturation [TSAT] greater than or equal to 20%) - Stable IV (epoetin alfa or beta) or SC rHuEPO (epoetin beta) therapy 2 or 3 times per week for at least 8 weeks before screening (stable is defined as less than 25% change in weekly dose and no change in frequency or route) - All subjects must practice adequate contraception (in the judgment of the investigator) throughout this trial.
排除标准
- •Received SC epoetin alfa in the 12 months before screening - Uncontrolled hypertension (diastolic blood pressure greater than 100 mmHg or systolic blood pressure greater than 180 mmHg on 2 separate occasions during screening) - Prior history (within 12 weeks before enrolment) of cardiovascular events including:
- •acute myocardial ischemia;
- •hospitalization for congestive heart failure;
- •myocardial infarction. - Pregnant or breast-feeding women - Treatment with an investigational agent or device within 30 days before screening or scheduled to receive an investigational agent other than those specified by this protocol during the course of this study - Known sensitivity to any of the products to be administered during dosing - Disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures
结局指标
主要结局
Treatment period 1: Mean haemoglobin during the evaluation period (weeks 21-24)
Treatment period 2: Mean haemoglobin during evaluation period 2 (weeks 45-48)
次要结局
- Treatment period 2: Change in Hb between Evaluation Period 1 and Evaluation Period 2
- Treatment period 1:The proportion of subjects with a mean Hb > 11.0 g/dL during the evaluation period
- Treatment period 2: The proportion of subjects with a mean Hb > 11.0 g/dL during Evaluation Period 2
- Treatment period 1: Dose and frequency of darbepoetin alfa administration over the treatment period
- Treatment period 2: The proportion of subjects with a change in Hb between Evaluation Period 1 and Evaluation Period 2 within the inclusive range -1.0 to +1.5 g/dL
- Treatment period 1: Change in Hb between screening/baseline and the evaluation period
- Treatment period 2: Dose and frequency of darbepoetin alfa administration over the treatment period
研究者
相似试验
已完成
2 期
A Study of Four Dosing Regimens of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease. Protocol Addendum: Extension Study of Maintenance Therapy of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease.Chronic Kidney DiseaseAnemiaNCT00212875Johnson & Johnson Pharmaceutical Research & Development, L.L.C.267
已完成
2 期
A Study of LGD-6972 in Patients With Type 2 Diabetes MellitusType 2 Diabetes MellitusNCT02851849Ligand Pharmaceuticals148
终止
不适用
A Randomized Clinical Trial on Hemoglobin Dose and Patient MatchingAnemiaNCT01328262Haukeland University Hospital12
终止
4 期
A Dose Conversion Study of Epoetin Alfa in Subjects With the Anemia of Chronic Kidney Disease.Chronic Renal InsufficiencyAnemiaNCT00495365Ortho Biotech Products, L.P.8
已完成
3 期
Treatment for Patients With Non-Myeloid Malignancies Receiving ChemotherapyNon-Myeloid MalignanciesCancerNCT00111137Amgen718